Corbus Pharmaceuticals (CRBP) announced that data from its US and UK conducted first-in-human dose escalation clinical study of CRB-701 is ...
In a report released on February 11, Brian Abrahams from RBC Capital maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback